MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E
Article in OncoTargets and Therapy (April 2024)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in OncoTargets and Therapy (April 2024)
Article in Cancer Treatment Reviews (January 2024)
Article in Reactions Weekly (January 2023)